@StockhammerPaul

Heme-Onc Fellow at @YaleCancer. Interested in #HER2 and #EGFR driven lung cancer. #LCSM

medicine.yale.edu/profile/paul-stockhammer/
Joined July 2022
  • Tweets291
  • Following446
  • Followers521
Excited for receiving this award from @lcrf_org / @Boehringer to model and study HER2-mutated lung cancer! 🧬🫁 @YaleCancer @SmilowCancer #LCSM
Lung Cancer Research Foundation@lcrf_org9 Dec 2025
Announcing the 2025 LCRF | Boehringer Ingelheim Early Career Investigator Awards: three awardees each received a $250k grant for projects focused on HER2-driven lung cancer. Read more about these scientists and the focus of their studies. LCRF.org/251209bi
Photos of two woman and one man, with the caption, early investigator award on innovative approaches toward the treatment of HER2-driving lung cancer

ALT Photos of two woman and one man, with the caption, early investigator award on innovative approaches toward the treatment of HER2-driving lung cancer

1
2
1
22
6,791
Paul Stockhammer retweeted
IASLC
@IASLCOct 9
📣 Abstract submissions are open for #TTLC27! Fellows and junior faculty: Share your research with the thoracic oncology community and contribute to the conversation shaping the future of precision medicine in lung cancer. 📅 Submit by Nov. 23: bit.ly/475OfQA
1
9
2
20
1,494
Paul Stockhammer retweeted
d.planchard@dplanchardSep 15
Time to start understanding mechanisms of resistance to zongertinib, which is rapidly becoming the standard of care (efficiency/toxicity ratio and BM efficacy) for our #HER2-mut NSCLC pts. Sequential tissue biopsies are key, but remain highly challenging.#WCLC2026
15
55
2,937
Paul Stockhammer retweeted
Hidehito HORINOUCHI
@HHorinouchiSep 15
🆙 #WCLC26 #LCSM Mini Oral Session 🔥 SOHO-01: Molecular Landscape of Acquired Resistance to Sevabertinib in HER2-mutant NSCLC 🎯85 pts with paired BL-PD plasma NGS 🎯Resistance-associated events in 30.1% 🎯Secondary HER2 T862A 16.4%, HER2 amplification　2.7%; C805S not detected 🎯Bypass/downstream alterations less frequent (PIK3CA/PTEN, MAPK pathway, 12.3%) 🎙️ @LeXiuning 🔢 MO12.04 ☑️ NCT05099172 🔗 cattendee.abstractsonline.co… @OncoAlert @Larvol @IASLC
Hidehito HORINOUCHI
@HHorinouchiAug 31
🆙 #WCLC26 #LCSM Mini Oral Session 🔥 SOHO-01: Molecular Landscape of Acquired Resistance to Sevabertinib in HER2-mutant NSCLC 🎯85 pts with paired BL-PD plasma NGS 🎯Resistance-associated events in 30.1% 🎯Secondary HER2 T862A 16.4%, HER2 amplification　2.7%; C805S not detected 🎯Bypass/downstream alterations less frequent (PIK3CA/PTEN, MAPK pathway, 12.3%) 🎙️ @LeXiuning 🔢 MO12.04 ☑️ NCT05099172 🔗 cattendee.abstractsonline.co… @OncoAlert @Larvol @IASLC
2
12
19
3,509
😳 Disappointing results of T-DXd in large randomized phase III Destiny-Lung04 first line in HER2mut NSCLC vs SoC chemo-pembro. Although control arm outperformed, the lack of translation into OS benefit and the concerning safety issues of this agent warrants a lot of discussion, specially in the upcoming data from selective HER2 TKIs, with are associated with better tolerance and safety profile. #WCLC26 @iasclc #lcsm
4
36
6
100
18,920
Paul Stockhammer retweeted
AASLD Foundation@AASLDFoundationSep 3
Congratulations to Daniela Goyes, MD, MHS, recipient of the Kimberly A. Brown Advanced/Transplant #Hepatology Fellow Award! Join us in celebrating this well-deserved honor.
1
1
4
15
7,290
Paul Stockhammer retweeted
JTO & JTO CRR
@JTOonlineAug 19
Clinico-genomic characteristics of NSCLC tumors with ERBB2 mutations beyond the TKD remain largely unexplored. But Stockhammer et al. present their findings which have implications for optimizing treatment strategies in NSCLC harboring ECD-ERBB2 mutations. 🔗 bit.ly/3U0ht05 #NSCLC #LungCancer #ERBB2 #HER2 #TargetedTherapy
5
8
543
Paul Stockhammer retweeted
Yale Cancer Center
@YaleCancerAug 17
.@MJGrantMD discusses his latest research on ERBB2-mutant lung cancer on the #JTOInsights podcast. Learn how activating mutations and co-occurring genomic alterations drive disease heterogeneity. jto.org/content/jto-insights @SmilowCancer @YaleThoracic
1
6
701
Paul Stockhammer retweeted
JTO & JTO CRR
@JTOonlineAug 13
🎧 New #JTOInsights episode! @DrAlexAdjei and @TommyJohn00 are joined by @MJGrantMD and @ChristianRolfo to explore new research on #ERBB2 -mutant lung cancer and molecular profiling across 80,000 patients with lung cancer. Listen now: bit.ly/3TWuTdl #JTOInsights #LungCancerResearch #JTO20 #lungcancer @IASLC
8
1
10
2,377
Paul Stockhammer retweeted
Hidehito HORINOUCHI
@HHorinouchiAug 6
🔥Exploring the continuum of HER2 TKD mutations & retiring the term "HER2 Exon 20 insertions" 🆙 @JTOonline 🎯HER2 mutations span TKD (75%), ECD (18%) & TMD/JMD (7%) 🎯Outdated: "One-size-fits-all" approach [TKD → HER2 TKIs; ECD → chemoimmunotherapy; TMD → HER2-ADC] 🎙Dr. Xiaosong Li @oncoOuLungCA #LCSM @OncoAlert @Larvol @Exon20Group jto.org/article/S1556-0864(2…

Exploring the Continuum of HER2 TKD Mutations and HER2 “Sensitizing Mutations” in NSCLC and...

Activating HER2 mutations were first discovered in 2004, when they were mostly insertions in exon 20.1 Over the years, nonselective HER2 TKIs (such as afatinib, pyrotinib, and poziotinib), HER2...

jto.org
2
11
22
2,712
Paul Stockhammer retweeted
JAMA
@JAMA_currentAug 10
🧵 Among patients with advanced #EGFR-mutated non-small cell #LungCancer and concurrent TP53 mutations, first-line osimertinib plus chemotherapy was associated with longer progression-free survival vs osimertinib alone, with greater toxicity. ja.ma/3Sq0bZH
3
13
1
34
14,575
Paul Stockhammer retweeted
Balazs Halmos
@BalazsHalmosMDJun 19
Lets bring on the TROPs indeed! Thanks for highlighting our editorial on accompanying terrific paper by Liao et al demonstrating the potential utility of Trop2 targeting to eliminate drug persister cells- and thereby possibly reach the Holy Grail of long-term disease control for pts w EGFR-mutated NSCLC It was especially fun regrouping after many yrs with EGFR guru @SusumuKobayas10 of T790M fame w terrific help from Motohiro Izumi! #lcsm @Cancer_Cell cell.com/cancer-cell/abstrac…
Hidehito HORINOUCHI
@HHorinouchiJun 19
🔥Targeting drug-tolerant persister cells: Let's bring on the TROPs! 🆙 @Cancer_Cell ☑Anti-TROP2 ADCs target residual DTP population — "induce-target-kill" strategy to delay resistance 🎙Dr. Motohiro Izumi @SusumuKobayas10 @BalazsHalmosMD #LCSM @OncoAlert @Larvol @EGFRResisters cell.com/cancer-cell/fulltex…
2
12
2
40
6,348
Great to see our work on #HER2 mutations in #HER2 mutant #LungCancer out in print in @JTOonline. doi: 10.1016/j.jtho.2026.103708 💡We show that there is ⬆️ clinicogenomic variability among patients with #NSCLC tumors harboring different #HER2 activating mutations. 🫁
1
3
11
730
more replies
@TalalZarif1 @MJGrantMD @IASLC @Exon20Group @YaleCancer @YaleMed #LCSM
1
1
2
131
sciencedirect.com/science/ar…
1
2
168
Yale @ConquerCancerFd YIA Winners, past and present! Love the support ❤️@StockhammerPaul @RSharma128 @curtperrymdphd @AdrianaKahnMD
3
4
45
2,230
Paul Stockhammer retweeted
Daniela Goyes, MD, MHS@dgoyesvMay 19
Grateful to have completed my MHS in Clinical Investigation at @YaleMed 🎓 Thankful to my mentors at @YaleDigestive, colleagues, family, and friends for their support throughout this journey ✨ excited for what comes next! #MHS #Yale #MedTwitter
2
13
604
Meeting of the minds this morning at ASCO!
4
22
2,069
Several of our thoracic fellows spent the day at the @OncLive Lung Fellows Forum and one of them showed his hidden talent in ping pong!
3
17
1,778
Load more